Compare AbbVie Inc (ABBV) vs ARK Autonomous Technology & Robotics ETF (ARKQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs ARK Autonomous Technology & Robotics ETF — how do they compare? AbbVie Inc trades at $248.98 (market cap $441.94B), while ARK Autonomous Technology & Robotics ETF trades at $128.4. The key difference: AbbVie Inc pays a 2.77% dividend while ARK Autonomous Technology & Robotics ETF pays none. Which is the better fit depends on your goals.
| ABBV | ARKQ | |
|---|---|---|
Market Cap | $441.94B | — |
Sector | Health | Sector/Thematic |
52-Week High | $263.58 | $143.82 |
52-Week Low | $197.38 | $95.28 |
Enterprise Value | $506.19B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABBV trades at $247.91, up 0.76% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported Q2 2026 EPS of $3.65, beating expectations, and maintains strong profitability with a 71.48% gross margin. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer, reinforcing growth prospects beyond Humira's patent expiry.
Outlook is positive with analyst consensus target of $278.69, though high P/E of 70.05 and debt levels pose valuation and financial risks. Revenue growth driven by Skyrizi and Rinvoq offsets competitive pressures, but patent cliffs in the 2030s require monitoring. The stock offers dividend appeal with a $1.73 payout scheduled for August 2026.
ARKQ trades at $127.85, up 3.77% today, with a bullish technical signal from moving averages but a neutral reading from oscillators. The ETF focuses on autonomous technology and robotics, with recent news highlighting its exposure to SpaceX and defense stocks. Support and resistance levels indicate key price zones for near-term movement.
The outlook for ARKQ is supported by long-term themes in AI and robotics, though high RSI levels suggest caution. Risks include sector volatility and reliance on disruptive tech stocks. Analyst sentiment is mixed, with some recommending accumulation during dips for growth-oriented investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About ARK Autonomous Technology & Robotics ETF
ARKQ is an actively managed ETF that invests in autonomous technology and robotics. It focuses on disruptive innovations like autonomous mobility, electric vehicles, 3D printing, and energy storage, with holdings such as Tesla and Teradyne.
Read more on ARKQ →
